Piśmiennictwo:
1. Jarosz J, Hilgier M, de Walden-Gałuszko K, Kaczmarek Z. Leczenie bólów nowotworowych. W: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Red. Krzakowski M, et al. Onkologia w Praktyce Klinicznej 2007, 2009 i 2011 (w druku).
2. Deandrea S i wsp. Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology 2008;19:1985-1991.
3. IASP. International Association for Study of Pain. Subcommittee on taxonomy of pain terms: a list with definitions and notes on usage. Pain 1979;6:249-252.
4. Knudsen AK, Brunelli C, Kaasa S. Which variables are associated with pain intensity and treatment response in advanced cancer patients? – Implications for a future classification system for cancer pain. European Journal of Pain 2011;15:320-327.
5. Portenoy R, Hagen N. Breakthrough pain: definition prevalance and characteristics. Pain 1990;41:273-281.
6. Davies AN, et al. The management of cancer-related breakthrough pain: Recommendations of a task group of Science Committee of Association for Palliative Medicine of Great Britain and Ireland. Europ J Pain 2009.
7. Cancer Pain Relief. WHO Geneva 1986.
8.Tassinari D, Maltoni M. Systematic review on the role of transdermal buprenorphine for moderate to severe cancer pain: An EPCRP opioid guidelines project. Fifth Bristol Opioids Conference: Revising the EAPC recommendations on opioids in cancer pain. www.ntnu.no/c/document_library/get_file?uuid=63d6516f-4804.
9.Bannister K, Dickenson AH. Opioid hyperalgesia. Curr Opin Support Palliat Care 2010;4:1-5.
10. Fine PG, Portenoy RK. Establishing „Best Practices” for Opioid Rotation: Conclusions of an Expert Panel Journal of Pain and Symptom Management 2009;3:418-432.
11.http://www.palliativedrugs.com/opioid-dose-conversion-ratios.html
12.Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005;16:825e833.